419 related articles for article (PubMed ID: 33864629)
1. Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis.
Zimner Rapuch S; Divino V; Norrbacka K; Boye K; Lebrec J; Rosilio M; DeKoven M; Guerci B
Diabetes Ther; 2021 May; 12(5):1553-1567. PubMed ID: 33864629
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain.
Norrbacka K; Sicras-Mainar A; Lebrec J; Artime E; Díaz S; Tofé-Povedano S; Hernández I; Romera I
Diabetes Ther; 2021 May; 12(5):1535-1551. PubMed ID: 33860927
[TBL] [Abstract][Full Text] [Related]
3. GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data.
Divino V; Boye KS; Lebrec J; DeKoven M; Norrbacka K
Diabetes Ther; 2019 Jun; 10(3):1067-1088. PubMed ID: 31028689
[TBL] [Abstract][Full Text] [Related]
4. Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation.
Yu M; Xie J; Fernandez Lando L; Kabul S; Swindle RW
Clin Ther; 2016 Jan; 38(1):149-60. PubMed ID: 26706658
[TBL] [Abstract][Full Text] [Related]
5. Semaglutide Once-Weekly Persistence and Adherence Versus Other GLP-1 RAs in Patients with Type 2 Diabetes in a US Real-World Setting.
Uzoigwe C; Liang Y; Whitmire S; Paprocki Y
Diabetes Ther; 2021 May; 12(5):1475-1489. PubMed ID: 33837922
[TBL] [Abstract][Full Text] [Related]
6. The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): resource use and costs of treatment in clinical practice in France, Germany, and Italy.
Barrett A; Boye KS; García-Pérez LE; Giorgino F; Guerci B; Füchtenbusch M; Yu M; Sapin H; Dib A; Heitmann E; Federici MO; Lebrec J
J Med Econ; 2024; 27(1):866-879. PubMed ID: 38963346
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57).
Ishigaki Y; Strizek A; Aranishi T; Arai N; Imaoka T; Cai Z; Maegawa H
Diabetes Ther; 2021 Jan; 12(1):345-361. PubMed ID: 33300091
[TBL] [Abstract][Full Text] [Related]
8. GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries.
Divino V; DeKoven M; Khan FA; Boye KS; Sapin H; Norrbacka K
Diabetes Ther; 2017 Feb; 8(1):115-128. PubMed ID: 28070733
[TBL] [Abstract][Full Text] [Related]
9. Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide.
Alatorre C; Fernández Landó L; Yu M; Brown K; Montejano L; Juneau P; Mody R; Swindle R
Diabetes Obes Metab; 2017 Jul; 19(7):953-961. PubMed ID: 28181725
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population.
Nguyen H; Dufour R; Caldwell-Tarr A
Adv Ther; 2017 Mar; 34(3):658-673. PubMed ID: 28078541
[TBL] [Abstract][Full Text] [Related]
11. Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States.
Johnston SS; Nguyen H; Felber E; Cappell K; Nelson JK; Chu BC; Kalsekar I
Adv Ther; 2014 Nov; 31(11):1119-33. PubMed ID: 25408484
[TBL] [Abstract][Full Text] [Related]
12. Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United States.
Mody R; Huang Q; Yu M; Zhao R; Patel H; Grabner M; Landó LF
Diabetes Obes Metab; 2019 Apr; 21(4):920-929. PubMed ID: 30520248
[TBL] [Abstract][Full Text] [Related]
13. Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus in Italy: A Retrospective Cohort Study.
Federici MO; McQuillan J; Biricolti G; Losi S; Lebrec J; Richards C; Miglio C; Norrbacka K
Diabetes Ther; 2018 Apr; 9(2):789-801. PubMed ID: 29525885
[TBL] [Abstract][Full Text] [Related]
14. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
Nauck MA; Quast DR; Wefers J; Meier JJ
Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776
[TBL] [Abstract][Full Text] [Related]
15. The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months.
Guerci B; Giorgino F; Sapin H; Boye K; Lebrec J; Federici MO; Heitmann E; Dib A; Füchtenbusch M; García-Pérez LE
Diabetes Obes Metab; 2022 Dec; 24(12):2373-2382. PubMed ID: 35876235
[TBL] [Abstract][Full Text] [Related]
16. Is insulin the preferred treatment for HbA1c >9%?
Bloomgarden Z
J Diabetes; 2017 Sep; 9(9):814-816. PubMed ID: 28589542
[TBL] [Abstract][Full Text] [Related]
17. Higher Rates of Persistence and Adherence in Patients with Type 2 Diabetes Initiating Once-Weekly vs Daily Injectable Glucagon-Like Peptide-1 Receptor Agonists in US Clinical Practice (STAY Study).
Polonsky WH; Arora R; Faurby M; Fernandes J; Liebl A
Diabetes Ther; 2022 Jan; 13(1):175-187. PubMed ID: 34918213
[TBL] [Abstract][Full Text] [Related]
18. The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient-reported outcomes at 24 months.
Boye KS; Lebrec J; Dib A; Heitmann E; Federici MO; Yu M; Sapin H; Barrett A; Guerci B; Giorgino F; Füchtenbusch M; García-Pérez LE
Diabetes Obes Metab; 2023 Dec; 25(12):3453-3464. PubMed ID: 37712754
[TBL] [Abstract][Full Text] [Related]
19. Treatment persistence in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists in clinical practice in Sweden.
Svensson AM; Toll A; Lebrec J; Miftaraj M; Franzén S; Eliasson B
Diabetes Obes Metab; 2021 Mar; 23(3):720-729. PubMed ID: 33289287
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
Goldman JD
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):61-72. PubMed ID: 32910492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
